Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells

Blood

Volumn 92, Issue 4, 1998, Pages 1342-1349

  Guedez, Liliana ^a   Courtemanch, Laurel ^a   Stetler Stevenson, Maryalice ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE INHIBITOR OF METALLOPROTEINASE;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BURKITT LYMPHOMA; CELL DIFFERENTIATION; CELL GROWTH; GERMINAL CENTER; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032529290     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.4.1342     Document Type: Article

References (46)

1. Werb Z, Ashkenas J, Mecanley JF: Extracellular matrix remodeling as a regulator of stromal-epithelial interactions during mammary gland development, involution, and carcinogenesis. Braz J Med Biol Res 29:1087, 1996
2. Woessner JF: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB 5:2145, 1991
3. Verfaillie C, Hurley R, Bhatia R, McCarthy J: Role of bone marrow matrix in normal and abnormal hematopoiesis. Crit Rev Oncol Hematol 16:201, 1994
4. Stetler-Stevenson WG, Aznavoorian S, Liotta L: Tumor cell interaction with the extracellular matrix during invasion and metastasis. Ann Rev Cell Biol 9:541, 1993
5. Khokha R. Zimmer MJ, Graham CH, Lala PK, Waterhouse P: Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells. J Natl Cancer Inst 84:1017, 1994
6. Montgomery AM, Muellar BM, Resifeld RA, Taylor SM, De Clerk Y: Effect of tissue inhibitor of metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 54:5467, 1994
7. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iawata K: Growth promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. FEBS 298:29, 1992
8. Stetler-Stevenson WG, Bersch N, Golde DW: Tissue inhibitor of metalloproteinases-2 (TIMP-2) has erythroid potentiating activity. FEBS Lett 296:231, 1992
9. Corcoran ML, Stetler-Stevenson WG: Tissue inhibitor of metalloproteinases-2 (TIMP-2) stimulates fibroblasts proliferation via a cyclic adenosine 3′,5′-monophosphate (cAMP) dependent mechanism. J Biol Chem 270:13453, 1995
10. Hayakawa T, Yamashita K, Kishi J, Harigaya K: Tissue inhibitor of metalloproteinase-1 from a human bone marrow stromal cell line KM102 has erythroid potentiating activity, suggesting its possible functional role in hematopoietic environment. FEBS Lett 268:125, 1990
11. Uchijima M, Sato H, Fujii M, Seiki M: Tax proteins of human T-cell leukemia virus type 1 and 2 induce expression of the gene encoding erythroid potentiating activity (tissue inhibitor of metalloproteinases-1 TIMP-1). J Biol Chem 269:14946, 1994
12. Stetler-Stevenson M, Mansoor A, Lim MS, Fukushima P, Kerhl J, Marti G, Ptazynsk K, Wang J, Stetler-Stevenson WG: Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases (TIMPs) in reactive and neoplastic lymphoid cells. Blood 89:1708, 1997
13. Kossakowska AE, Urbanski SJ, Edwards DR: Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin's lymphomas. Blood 77:2475, 1991
14. Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A, Stetler-Stevenson M: In vitro suppression of programmed cell death of B-cells by tissue inhibitor of metalloproteinases-1 (TIMP-1). J Clin Invest, 1998 (Accepted)
15. Chantal L, Chantal B, Daniel PT, Krammer PH, Defrance T: Regulation of germinal center B cell differentiation. J Immunol 154:5746, 1995
16. Magrath I: The pathogenesis of Burkitt's lymphomas. Adv Cancer Res 55:133, 1990
17. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H, Rickinson AB: Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphomas. EMBO J 6:2743, 1987
18. Gregory CD, Dive C, Henderson S, Smith CA, Williams GT, Gordon J, Rickinson AB: Activation of Epstein-Barr-virus-latent genes protects human B cells from death by apoptosis. Nature 349:612, 1991
19. Cutrona G, Ulivi M, Fais F, Roncella S, Ferrarini M: Transfection of the c-myc oncogene into normal Epstein-Barr virus harboring B cells results in new phenotypic and functional features resembling those of Burkitt's lymphoma cells and normal centroblasts. J Exp Med 181:699, 1995
20. Taga S, Mangeney M, Tursz T, Wiels J: Differential regulation of glycosphyngolipid biosynthesis in phenotypically distinct Burkitt's lymphoma cell lines. Int J Cancer 61:261, 1995
21. O'Connor P, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn K: Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 53:4776, 1993
22. Bhatia K, Goldschmidts W, Gutierrez M, Gaidano G, Dalla-Favera R: Hemi-or homozygosity: A requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect. FASEBJ 7:951, 1993
23. Bhatia K, Fan S, Spangler G, Weintraub M, O'Connor PM, Judde JG, Magrath I: A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma. Cancer Res 55:1431, 1995
24. Oliver GW, Leferson JD, Stetler-Stevenson WG, Kleiner DE: Quantitative reverse zymography: Analysis using gelatinase A and B reverse zymograms. Anal Biochem 244:161, 1996
25. Rochford R, Hobbs MV, Garnier JL, Cooper NR, Cannon MJ: Plasmacytoid differentiation of Epstein Barr virus transformed B cells in vivo is associated with reduced expression of viral latent genes. Proc Natl Acad Sci USA 90:352, 1993
26. Tsubata T, Wu J, Honjo T: B cell apoptosis induced by antigen receptor crosslinking is blocked by a T cell signal through CD40. Nature 364:645, 1993
27. Lomo L, Blomhoff HK, Jacobsen SE, Skrajewski S, Reed JC, Smeland EB: Interlukin-13 in combination with CD40 ligand potentially inhibits apoptosis in human B lymphocytes: Upregulation of Bcl-xL and Mcl-1. Blood 89:4415, 1997
28. Wang F, Gregory CD, Sample C, Rowe M, Leibowitz D, Murphy R, Rickinson AB, Kieff E: Epstein-Barr virus latent membrane proteins (LMP-1) and nuclear protein 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP-1 cooperatively induce CD23. J Virol 64:2309, 1990
29. Letellier M, Nakajima T, Pulido-Cejudo G, Hofstetter H, Delespesse G: Mechanism of formation of human IgE-binding factors (soluble CD23): III Evidence for a receptor (FceRII)-associated proteolytic activity. J Exp Med 172:693, 1990
30. Murai H, Hara H, Hatae T, Kobayashi T, Watanabe T: Expression of CD23 in the germinal center of thymus from myasthemia gravis patients. J Neuroimmunol 76:61, 1997
31. Guedez L, Lim MS, Stetler-Stevenson WG: The role of metalloproteinases and their inhibitors in hematological disorders. Crit Rev Oncogenesis 7:205, 1996
32. Preece G, Murphy G, Ager A: Metalloproteinase-mediated regulation of L-selectin levels on leukocytes. J Biol Chem 17:11634, 1997
33. Tanaka M, Suda T, Haze K, Nakamura N, Sato N, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Dummond A, Nagata S: Fas ligand in human serum. Nature Med 2:317, 1996
34. Fyfe G, Cebra-Thomas JA, Mustain E, Davie JM, Alley CD, Nahm MH: Subpopulations of B lymphocytes in germinal centers. J Immunol 139:2187, 1987
35. Hardie DL, Johnson GD, Khan M, MacLennan ICM: Quantitative analysis of molecules which distinguish functional compartments within germinal centers. Eur J Immunol 23:997, 1993
36. Mangeney M, Richard Y, Coulaud D, Tursz T, Wiels J: CD77: An antigen of germinal center B cells entering apoptosis. Eur J Immunol 21:1131, 1991
37. Mangeney M, Lingwood CA, Taga S, Caillou B, Tusz T, Wiels J: Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res 53:5314, 1993
38. Mangeney M, Rousselet G, Taga S, Tursz T, Wiels J: The fate of human CD77 germinal center B lymphocytes after rescue from apoptosis. Mol Immunol 32:333, 1995
39. Liu YJ, Johnson GD, Gordon J, MacLennan ICM: Germinal centres in T-cell-dependent antibody responses. Immunol Today 13:17, 1992
40. Holder MJ, Wong H, Milner A E, Casamayor M, Armitage R, Spriggs MK, Fanslow WC, MacLennan ICM, Gregory CD, Gordon J: Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bcl-2 induction. Eur J Immunol 23:2368, 1993
41. Koopman G, Rechnen RMJ, Lindhout E, Zhou DFH, Groot C, Pals ST: Germinal center B cells rescued from apoptosis by CD40 ligation or attachment to follicular dendritic cells, but not by engagement of surface immunoglobulin or adhesion receptors, become resistant to CD95-induced apoptosis. Eur J Immunol 27:1, 1997
42. Krenacs T, van Dartel M, Lindhout E. Rosendal M: Direct cell/cell communication in the lymphoid germinal center: Connexin43 gap junctions functionally couple follicular dendritic cells to each other to B lymphocytes. Eur J Immunol 27:1489, 1997
43. Kossakowska A, Stefan SJ, Urbanski J, Watson A, Hayden LJ, Edwards DR: Patterns of expression of metalloproteinases and their inhibitors in human malignant lymphomas. Oncol Res 5:19, 1993
44. Alexander CM, Howard EW, Bissell MJ, Werb Z: Rescue of mammary epithelial cell apoptosis and entactin degradation by tissue inhibitor of metalloproteinase-1 transgene. J Cell Biol 135:1669, 1996
45. Mimori K, Mori M, Shiraishi T, Fujie T, Baba K, Haraguchi M, Abe R, Ueo H, Akiyoshi T: Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer 76:531, 1997
46. Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nestland JM, Fostad O: High levels of messenger-RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastasis. Clin Cancer Res 3:1623, 1997